CoChat

Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic

Open access
Cristino, Joaquim, Finek, Jíndřich, Jandova, Petra, Kolek, Martin, Pásztor, Bálint, Giannopoulou, Christina, Qian, Yi, Brezina, Tomas, Lothgren, Mickael · 2017 · Journal of Medical Economics

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

AIMS: This study assessed the cost-effectiveness of the subcutaneous RANKL inhibitor, denosumab, vs the intravenous bisphosphonate, zoledronic acid, for the prevention of skeletal-related events (SREs) in patients with prostate cancer, breast cancer, and other solid tumors (OST) in the Czech Republic. MATERIALS AND METHODS: A lifetime Markov model was developed to compare the effects of denosumab and zoledronic acid on costs (including drug costs and administration, patient management, SREs, and adverse events), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios from a national payer perspective. Different discount rates, time horizons, SRE rates, distributions, and nature (asymptomatic vs all SREs), and the inclusion of treatment discontinuation were considered in scenario analyses. The robustness of the model was tested using deterministic and probabilistic sensitivity analyses. RESULTS: Across tumor types, denosumab was associated with fewer SREs, improved QALYs, and higher total costs over a lifetime. The incremental cost per QALY gained for denosumab vs zoledronic acid was 382,673 CZK for prostate cancer, 408,450 CZK for breast cancer, and 608,133 CZK for OST. Incremental costs per SRE avoided for the same tumor type were 54,007 CZK, 51,765 CZK, and 94,426 CZK, respectively. In scenario analyses, the results remained similar to baseline, when different discount rates and time horizons were considered. At a non-official willingness-to-pay threshold of 1.2 million CZK, the probabilities of denosumab being cost-effective vs zoledronic acid were 0.64, 0.67, and 0.49 for prostate cancer, breast cancer, and OST, respectively. LIMITATIONS: The SRE rates used were obtained from clinical trials; studies suggest rates may be higher in clinical practice. Additional evidence on real-world SRE rates could further improve the accuracy of the modeling. CONCLUSIONS: Compared with zoledronic acid, denosumab provides a cost-effective treatment option for the prevention of SREs in patients with prostate cancer, breast cancer, and OST in the Czech Republic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/13696998.2017.1328423

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 2

  1. Barton GR, 2008, Health, 11, 886
  2. International Agency for Research on Cancer, WHO. Chapter 2: Rates and rate standardization. In: N.E. Breslow and N.E. Day Eds Statistical methods in cancer research volume II: the design and analysis of cohort studies. Lyon, France: Oxford University Press; 1987, pp 48-81

Cited by

See all 17

Metadata

Authors
Cristino, J., Finek, J., Jandova, P., Kolek, M., Pásztor, B., Giannopoulou, C., Qian, Y., Brezina, T., & Lothgren, M.
Affiliations
  • Amgen (Switzerland) (CH)
  • Pilsen Faculty Hospital, Clinic of Oncology and Radiotherapy (FN v Plzni), Pilsen, Czech Republic;
  • Amgen s.r.o., Prague, Czech Republic;
  • Oaks Consulting, Prague, Czech Republic;
  • Amgen (United States) (US)
  • Amgen (Europe) GmbH, Zug, Switzerland;
Venue
Journal of Medical Economics
Published
2017-06-07
Volume
20
Issue
8
Pages
799-812
ISSN
  • 1369-6998 (ISSN-L)
  • 1941-837X
OpenAlex
W2613642134
Cited by
16
References
43
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 1
FWCI
0.60
Type
journal article
Language
en
Open access
Locations
  • Journal of Medical Economics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Keywords
denosumab, zoledronic acid, cost-effectiveness, skeletal-related events, RANKL inhibitor, bisphosphonates, prostate cancer, breast cancer, solid tumors, quality-adjusted life years, incremental cost-effectiveness ratio, Czech Republic
MeSH terms
Denosumab, Zoledronic Acid, Bone Diseases, Breast Neoplasms, Cost-Benefit Analysis, Diphosphonates, Double-Blind Method, Female, Humans, Imidazoles, Male, Markov Chains, Neoplasms, Prostatic Neoplasms, Quality of Life, Models, Econometric, Czech Republic, Quality-Adjusted Life Years, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. https://app.cochat.ai/papers/10.1080/13696998.2017.1328423
The paper
Cristino, J., Finek, J., Jandova, P., Kolek, M., Pásztor, B., Giannopoulou, C., Qian, Y., Brezina, T., & Lothgren, M. (2017). Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. Journal of Medical Economics. https://doi.org/10.1080/13696998.2017.1328423

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.